Detail akcie Anika Therapeut online

Business Summary: Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Anika Therapeutics Inc revenues increased 13% to $29.6M. Net loss before extraordinary items increased 28% to $5.1M. Revenues reflect OEM Channel segment increase of 14% to $17M, Commercial Channel segment increase of 12% to $12.6M, United States segment increase of 13% to $18.5M, Europe segment increase of 15% to $6.7M.